Novartis Release - Neoral.

(From Hugin)

Results of LIS2T study indicate that Neorala is associated with less diabetes and diarrhoea than tacrolimus in liver transplantation New study data found that liver transplant patients receiving Neoral (cyclosporin for microemulsion) and managed by C2 monitoring experience significantly less diabetes and diarrhoea compared to those given tacrolimus. Basel, 23 June 2003 - Neorala is as effective as tacrolimus in preventing acute rejection in liver transplant patients whilst also being better tolerated according to the 6 month analysis of the …